Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Pietra

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Leukemia|December 22, 2020
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2<sup>P95</sup>-mutated neoplasmsGabriele Todisco, Maria Creignou, Anna Gallì, et al.
Blood|December 25, 2013
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomesElisa Rumi, Daniela Pietra, Virginia Ferretti, et al.
Blood|January 13, 2011
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutationsFrancesco Passamonti, Chiara Elena, Susanne Schnittger, et al.
Blood|May 10, 2015
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblastsLuca Malcovati, Mohsen Karimi, Elli Papaemmanuil, et al.
American Journal of Hematology|April 3, 2016
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM groupGiada Rotunno, Annalisa Pacilli, Valentina Artusi, et al.
Blood|July 3, 2014
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisElisa Rumi, Daniela Pietra, Cristiana Pascutto, et al.
Blood|May 9, 2019
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasmsFiorella Schischlik, Roland Jäger, Felix Rosebrock, et al.
International Journal of Cancer|November 9, 2015
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosisSimona Salati, Roberta Zini, Simona Nuzzo, et al.
Haematologica|November 13, 2008
Concordance of assays designed for the quantification of JAK2V617F: a multicenter studyEric Lippert, François Girodon, Emma Hammond, et al.
Blood|August 7, 2014
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesisRuggiero Norfo, Roberta Zini, Valentina Pennucci, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Leukemia|December 22, 2020
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2<sup>P95</sup>-mutated neoplasmsGabriele Todisco, Maria Creignou, Anna Gallì, et al.
Blood|December 25, 2013
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomesElisa Rumi, Daniela Pietra, Virginia Ferretti, et al.
Blood|January 13, 2011
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutationsFrancesco Passamonti, Chiara Elena, Susanne Schnittger, et al.
Blood|May 10, 2015
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblastsLuca Malcovati, Mohsen Karimi, Elli Papaemmanuil, et al.
American Journal of Hematology|April 3, 2016
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM groupGiada Rotunno, Annalisa Pacilli, Valentina Artusi, et al.
Blood|July 3, 2014
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisElisa Rumi, Daniela Pietra, Cristiana Pascutto, et al.
Blood|May 9, 2019
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasmsFiorella Schischlik, Roland Jäger, Felix Rosebrock, et al.
International Journal of Cancer|November 9, 2015
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosisSimona Salati, Roberta Zini, Simona Nuzzo, et al.
Haematologica|November 13, 2008
Concordance of assays designed for the quantification of JAK2V617F: a multicenter studyEric Lippert, François Girodon, Emma Hammond, et al.
Blood|August 7, 2014
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesisRuggiero Norfo, Roberta Zini, Valentina Pennucci, et al.
Pageof 10